menu
    • menu
    [{"orgOrder":0,"company":"Elixiron Immunotherapeutics","sponsor":"Alzheimer\u2019s Association","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"TAIWAN","productType":"Other Small Molecule","year":"2020","type":"Funding","leadProduct":"EI-1071","moa":"CSF-1 receptor","graph1":"Neurology","graph2":"Phase I","graph3":"Elixiron Immunotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Elixiron Immunotherapeutics \/ Alzheimer\u2019s Association","highestDevelopmentStatusID":"6","companyTruncated":"Elixiron Immunotherapeutics \/ Alzheimer\u2019s Association"},{"orgOrder":0,"company":"Elixiron Immunotherapeutics","sponsor":"Pangu Capital","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"TAIWAN","productType":"Other Small Molecule","year":"2021","type":"Series A Financing","leadProduct":"EI-1071","moa":"CSF-1 receptor","graph1":"Neurology","graph2":"Phase I","graph3":"Elixiron Immunotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Elixiron Immunotherapeutics \/ Pangu Capital","highestDevelopmentStatusID":"6","companyTruncated":"Elixiron Immunotherapeutics \/ Pangu Capital"}]

    Find Clinical Drug Pipeline Developments & Deals by Elixiron Immunotherapeutics

    Menu

    Elixiron Immunotherapeutics

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Elixiron Immunotherapeutics

                            Taiwan arrow
                            IOPC
                            Not Confirmed

                            Elixiron Immunotherapeutics

                            Taiwan arrow
                            IOPC
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : EI-1071

                            Therapeutic Area : Neurology

                            Study Phase : Phase I

                            Sponsor : Pangu Capital

                            Deal Size : $27.0 million

                            Deal Type : Series A Financing

                            DEALS_DEV arrow-down

                            Elixiron Immunotherapeutics Announces Closing of $27 Million Series A-1 Financing Round to Progress Alzheimer'...

                            Details : Proceeds will be used to advance phase 1 trials of two pipeline candidates, EI-1071 and EI-001 and take three immuno-oncology assets towards IND applications .

                            Product Name : EI-1071

                            Product Type : Other Small Molecule

                            Upfront Cash : Undisclosed

                            August 23, 2021

                            Lead Product(s) : EI-1071

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase I

                            Sponsor : Pangu Capital

                            Deal Size : $27.0 million

                            Deal Type : Series A Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Elixiron Immunotherapeutics

                            Taiwan arrow
                            IOPC
                            Not Confirmed

                            Elixiron Immunotherapeutics

                            Taiwan arrow
                            IOPC
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : EI-1071

                            Therapeutic Area : Neurology

                            Study Phase : Phase I

                            Sponsor : Alzheimer’s Association

                            Deal Size : $1.0 million

                            Deal Type : Funding

                            DEALS_DEV arrow-down

                            Elixiron Immunotherapeutics Awarded Alzheimer's Association Grant to Target Microglia in Alzheimer's Disease

                            Details : Grant Program will support a U.S. FDA-approved first-in-human phase 1 clinical trial of its lead drug candidate, EI1071, an orally available, highly potent Colony-Stimulating Factor 1 Receptor (CSF1R) inhibitor.

                            Product Name : EI-1071

                            Product Type : Other Small Molecule

                            Upfront Cash : Undisclosed

                            August 26, 2020

                            Lead Product(s) : EI-1071

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase I

                            Sponsor : Alzheimer’s Association

                            Deal Size : $1.0 million

                            Deal Type : Funding

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth